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MAN MADE ORGANS: TECHNOLOGY MADE IT POSSIBLE 
BUT CAN THE FDA KEEP UP? 
AMANDA CHATMAN 
INTRODUCTION 
A transplant surgeon has five patients that each need a different organ to 
survive.  There are no organs available to perform any of these five trans-
plant operations.  A healthy young man comes in for a routine checkup.  In 
the course of doing the checkup, the doctor discovers that his organs are 
compatible with all five of his dying patients.  Suppose further that the 
young man has no family members or friends and would not be missed if he 
were to disappear.  Should the young, healthy, unattached man die for the 
greater good of saving five lives?  This ethical problem, commonly used in 
philosophical discussions, is designed to make us consider the effect of one 
human sacrifice for the greater good.  These utilitarian discussions have 
been occurring for centuries, and other than choosing one life over another, 
there have not been any real viable answers, until now. The recent ad-
vancements in a procedure called bioprinting may make this organ trans-
plant hypothetical moot. 
Bioprinting refers to the creation of cartilage, bone, skin, prosthetics, and 
even living organs using a three-dimensional printing device.1  Bioprinting 
is currently used to create prosthetics and training devices for surgeons, but 
is quickly growing into a source for organs to be used in transplants.2  Alt-
hough this amazing technology could solve the transplant problem de-
scribed above, it also raises numerous ethical questions that could lead to 
legal bans.3  The future of bioprinting will depend on how the technology is 
regulated in upcoming years.  History illustrates that regulation is slow to 
catch up to technology and that will be a major problem for the survival of 
bioprinting.  This comment will discuss the history of bioprinting and its 
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expected growth, the ethical implications, necessary regulation, and the 
burden on the Federal Food and Drug Administration to adapt and change 
with this new technology. 
BACKGROUND: BIOPRINTING EXPLAINED AND THE CHALLENGES TO THE 
FDA 
Over the past few decades, printing has evolved from two-dimensional 
printing to an “additive process in which successive layers of material are 
distributed to form three-dimensional (3D) shapes.”4  Currently, the most 
common uses of 3D printers are to enable rapid prototyping and manufac-
turing and to produce personalized products in the home.5  Three-
dimensional printing is also being used in science and education for the 
purpose of producing replicas of rare artifacts and models of complex mol-
ecules and protein interactions.6 
Charles W. Hugh was the first person to describe 3D printing.7  His 
method of 3D printing described the layering of thin materials that could be 
cured with an ultraviolet light to form a solid 3D structure.8  This layering 
process was later used to create “sacrificial resin molds for the formation of 
3D scaffolds from biological materials.”9  These 3D scaffolds could be used 
for transplantation with or without seeded cells.10  This led to the use of 3D 
bioprinting as a form of tissue engineering.11 
In bioprinting, plastic and other materials used to create structures with 
3D printing are replaced with sensitive, living biological materials.12  The 
biological materials are precisely layered with spacial control of the place-
ment of functional components to fabricate 3D functional living human 
constructs with biological and mechanical properties suitable for clinical 
restoration of tissue and organ function.13  Organ bioprinting is based on 
stem cells which serve as the initial material for the bio-ink.14  Stem cells 
can serve as the building material for any of the body’s tissues.15  The pa-
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tient’s cells are aggregated in layers according to a preset digital organ de-
sign to form “spheroids” onto hydrogel.16 Once the gel dissolves, the 
“printed organ is placed in to a special bio reactor where it matures.”17  
Once the organ matures, it is ready to be implanted into the patient.  Since 
the bioprinted organ is made out of the patients’ own cells, the patients’ 
body should not reject the organ. 
Although there has not been a human transplant of a solid bioprinted or-
gan to date, surgeons have successfully implanted hollow tissues into pa-
tients including skin, cartilage and muscles.18  There have also been suc-
cessful transplants of bladders and urethras into young patients.19  The 
world’s first 3D human liver was printed in 2013 and used solely for re-
search purposes.20  Despite the fact that many did not expect bioprinted 
organs to be transplant ready for many years, Russia has announced that its 
first transplant ready organ, a thyroid, will be released in 2015.21  Russian 
Scientists plan to begin their experiment on the thyroid, with further work 
on a functional printed kidney scheduled for 2018.22 
In order for bioprinting to be used for the creation of viable transplant 
organs, it is crucial that the United States Food and Drug Administration 
(hereinafter “the FDA”) adjust its approach to the regulation of new medi-
cal technology.  Technology grows much faster than the pace at which the 
FDA regulates.  The FDA must take on a more flexible and responsive ap-
proach to the regulation of bioprinting technology in order for bioprinting 
to revolutionize the healthcare industry. 
Although bioprinting has the potential to save many human lives through 
the production of living human organs, without proper regulation it can 
cause serious harm to both individuals and society as a whole.  Bioprinting 
is a unique hybrid of technology and biology which makes it a difficult area 
to regulate and oversee.23  Bioprinting does not fit within a traditional FDA 
category of “device” or “biologic” and that will require the FDA to rethink 
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its regulation process.24  The FDA took note of this challenge when they 
decided to form a “Program Alignment Group” tasked to identify and de-
velop “plans to modify FDA’s functions, processes, and possibly its struc-
ture in order to address these matters”.25  The FDA is attempting to modify 
their approach to regulation because technology has transformed the devic-
es and drugs being produced today.  Their past approach was built around 
distinguishing products and devices into separate categories, but these cate-
gories are now intertwined with one another making their current regulation 
process less effective.26 
Although it is clear that this reorganization is necessary, what does it 
mean for a technology, such as bioprinting, that is in dire need of regulation 
now?  It means that the FDA must make this reorganization effective and 
do so quickly. A major change in the structure and formation of a govern-
ment agency’s function can be difficult.  It can take many years to break up 
a government agency’s existing divisions to adopt new programs.  Based on 
the FDA’s history, it does not adapt to change quickly if at all.27  In 2002, 
the FDA announced a reorganization that would merge the FDA’s drug 
center with its biologics center.28  Due to internal resistance to the change, 
this merger was largely rolled back two years later.29  Not only does the 
FDA face the challenge of reorganizing its regulation methods, it must also 
overcome the internal resistance it will face in order to allow new technolo-
gy such as bioprinting to reach its potential as a health care tool. 
There are “currently no government regulations on bioprinting, 
bioprinted products or the machines.”30  The FDA has only addressed the 
regulation of 3D printed medical devices that do not involve living biologic 
materials.31  In recent years, it has become common practice to use 3D 
printers to produce customized devices such as hearing aids, dental im-
plants, and surgical instruments.32  Although these 3D printed medical de-
vices have become common, the FDA has yet to create custom regulations 
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for such products.33  The FDA currently assesses “3D printed medical de-
vices and conventionally made products under the same guidelines, despite 
the different manufacturing methods involved.”34  The FDA is just now 
beginning to consider different methods for regulating 3D printed devices 
and have yet to officially implement new procedures.  It is vital that the 
FDA take a more proactive approach to regulating the use of bioprinters.  
Since bioprinters combine human cells with 3D printing technology, leav-
ing regulation as it is and only tweaking it once the technology is common-
ly used would likely result in a dangerous outcome. 
FDA regulation is necessary because bioprinting raises many ethical 
questions that involve the well-being of patients and society as a whole.  
There are questions that need to be heavily discussed and answered before 
bioprinting of living organs can become a reality.  One of the most alarming 
questions regards the possibility that bioprinting could lead to “dystopian 
immortality in individuals that can afford to have organs repaired or re-
placed as they wear out.”35  Although attainable immortality in itself may 
seem like an overwhelming thought, what is more concerning is the effect 
this could have on society.  It is most likely that money would decide who 
receives a new organ and who does not, which translates into money deter-
mining who lives and who dies.36  The cost of functional organs produced 
from a bioprinter will only be available to those financially capable of pay-
ing for such personalized treatments.37  This will continue to expand the 
access divide between the rich and the poor. 
Regulation is necessary to control the purpose of bioprinting.  Another 
issue to be regulated is the possibility that bioprinting could become related 
to performance enhancement in professional sports.38  Athletes will have 
the capability to use bioprinting as a tool to repair injured tissues or muscles 
or even replace natural muscles with synthetic ones which could unnatural-
ly advance human capabilities.39  This could also lead to the use of 
bioprinting for cosmetic purposes.  Individuals could design their own nose, 
ear, or chin as opposed to trusting the plastic surgeon to construct one out 
of their existing body parts.  Although this may not seem extreme, where 
does it end?  If there are no restrictions on the use of the body part or the 
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amount created, it is plausible that bioprinting could lead to the construction 
of a synthetic human. 
Another issue that is likely to result from the bioprinting of organs is the 
illegal buying and selling of synthetic organs.  Just as there is currently a 
black market for human organs, a bioprinted black organ market may result 
from the advancement of bioprinting.40   The possibility that individuals 
will bioprint organs to make a profit is potentially more dangerous than the 
current black market that distributes human organs.  Bioprinted organs are 
designed and manipulated by a person and then produced by a machine.  
There are many more opportunities for error when the organ is being con-
structed by man and machine than there are when dealing with a human 
organ. 
ANALYSIS: THE SOLUTION 
Although the bioprinting of human organs has not yet been used in hu-
man transplants, the issues that must be dealt with when bioprinting is 
commonly used are readily apparent.  The FDA needs to alter its regulation 
approach and begin putting regulations in place now that will guide the 
mainstream use of bioprinting rather than waiting until the damage has al-
ready been done.  The FDA should: (1) develop a detailed plan regarding 
how bioprinted organs will be distributed; (2) develop guidelines for deter-
mining the eligibility for the allocation of bioprinted organs and tissue; and 
(3) determine who will control and monitor the production of human or-
gans. 
(1) Developing a detailed plan regarding how bioprinted organs will 
be distributed 
The FDA currently regulates human cells or tissues intended for implan-
tation, transplantation, infusion, or transfer into a human recipient, while 
The Health Resources and Services Administration (hereinafter “the 
HRSA”) oversees the donation and transplantation of vascular organs, such 
as hearts, livers, and kidneys.41  The HRSA governs the entire organ donor 
process from placing a patient on the waiting list, to matching the patient to 
an available organ, to the transplant surgery.  Bioprinting technology will 
drastically change the process of events for patients in need of an organ and 
this will create the need for a new process in the acquisition of a new organ. 
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Patients will no longer have to go through the process of being put on a 
waiting list, waiting to see if a person who is a match for their specific 
transplant dies, going through the transplant surgery, and then waiting to 
see if their body accepts or rejects the organ.  Although there has yet to be 
determined an exact process regarding the patient experience with 
bioprinting, it is likely that a doctor will remove cells from the patient and 
have those cells used in the production of the necessary organ.  Once the 
organ has been produced, the doctor will remove the defective organ and 
replace it with the bioprinted organ.  The bioprinting process revolves 
around the doctor and the bioprinter.  There is no longer a third party in-
volved, nor is there a risk that the patient’s body will reject the organ. 
Since bioprinting is centered on the bioprinter itself, which is a device, it 
would be more efficient to have the FDA regulate the organ donor process 
as opposed to the HRSA. The FDA already regulates human tissues, and 
medical devices.  Bioprinting combines a medical device and human cells 
and tissues to create the organ to be transplanted.  Therefore, it seems most 
reasonable for the FDA to maintain the utmost control over the safety of the 
transplants and the distribution of the organs. 
The method of distribution will determine whether the ethical issue of 
“dystopian immortality” truly becomes a reality.42  In establishing a distri-
bution plan for bioprinted organs, it is crucial that the FDA find a middle 
ground between the economic requirements of this technology and those in 
need of bioprinted organs.  The FDA must prevent bioprinting from becom-
ing a luxury for the wealthy.  It must be integrated into the health care sys-
tem in order to become available to individuals of all economic classes. 
The FDA should take an approach similar to the current system in which 
patients receive organs according to their position on a list. The main dif-
ference exists in recognizing that patients are no longer waiting for a match, 
but are waiting for a custom creation of an organ made from their own 
cells.  It may be effective to separate patients into two groups; those in im-
minent need of an organ and those that can survive without an immediate 
transplant.  This separation would mirror how hospitals separate patients, in 
that those in need of critical care are in the intensive care unit while patients 
with less serious injuries or illnesses are not in a specialized unit.  This sep-
aration would allow the appropriate attention to each patient depending on 
their condition, absent regard to their economic status.  Patients would not 
be able to buy their way into a bioprinted organ because their treatment 
would be based on their specific condition.  Although the cost of the 
bioprinted organ itself may have an effect on who is able to receive it, in-
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surance companies and their regulations regarding bioprinting would deal 
with the issue. 
(2) Developing guidelines for determining the eligibility for allocation 
of bioprinted organs and tissue 
Determining who is and is not eligible for donor organs has always been 
a controversial issue. Based on the number of patients in need of a donor 
organ and the few organs that become available, eligibility is determined by 
a number of psychosocial factors, including age, mental health, and intelli-
gence.43  Allocation decisions have been made by donor programs, hospital 
administrators and even physicians.44  This method has contributed greatly 
to the accusations of bias allocation and discriminatory allocation.45 This 
method would likely be just as inconsistent when dealing with bioprinted 
organs. 
As suggested by many medical professors and professionals, government 
entities may “have the strongest claim to authority to make organ allocation 
decisions.”46  Although this solution does not guarantee complete fairness, 
by setting out allocation guidelines prior to the mainstreaming of bioprinted 
organs, there will be infrastructure for assuring that this technology is being 
used in the proper situations. 
Currently, one of the largest issues regarding organ allocation is that pa-
tients with disabilities are being discriminated against.  Although this issue 
may exist when bioprinting is used for organ transplant, a larger concern is 
that bioprinting will be used for cosmetic or advancement purposes.  There 
must be limits set on what type of replacement or treatment bioprinting will 
be used for in order to avoid the unnatural advancement of human capabili-
ties.47  The most effective way to do this is for the FDA to begin setting 
those limitations now. 
There are two sides to the creation of enhanced organs, also referred to as 
“superorgans.”48  The first is the idea of creating organs that have the capa-
bilities to fight off disease or contribute to the health of the human body.  
The possibility of engineering artificial organs to perform specific, useful 
functions, such as treating disease is already being discussed by scientists.49  
In fact, a 3D printed artificial pancreas that can regulate glucose levels in 
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diabetic patients is being developed at the University of Iowa’s Advanced 
Manufacturing Technology Group.50  Scientists are thinking as extreme as 
bioprinted organs that can generate electricity in the human body in order to 
power electronic implants like pacemakers without the need for batteries.51  
These functions seem reasonable in that they intend to contribute to human 
health. 
The second side of the creation of “superorgans” is the idea that body 
parts can be created to allow for performance or cosmetic enhancements.  
There has been a battle in the professional sports industry for years against 
the use of performing enhancement drugs, such as steroids.  Bioprinting 
technology could potentially be used for performance enhancement purpos-
es and could easily exceed the capabilities of any existing performance en-
hancing drug.  Bioprinting would allow the creation of new muscles with 
capabilities that surpass those of natural human muscles even with drug 
enhancements.  Not only could this be a problem for professional sports, 
but it could be an issue for law enforcement.  If individual citizens were 
able to acquire superhuman muscles, traditional police powers may not 
have the same control over them, thereby creating a threat to the safety of 
others. 
The FDA should limit the use of bioprinting to the replacement of organs 
and tissue necessary for the survival of patients during the first few years of 
its use.  Once the number of individuals in need of a bioprinted organ is 
under control, the FDA should expand its eligibility requirements to include 
patients seeking a bioprinted transplant for the purpose of improving human 
health.  The FDA should have strict regulations in place to prevent the use 
of bioprinters for muscle or organ enhancement for the sole purpose of im-
proving physical performance. 
(3) Determining who will control and monitor the production of human 
organs 
One of the greatest problems regarding bioprinting is the factor of control 
over the production of organs.  Control is necessary to prevent the creation 
of unauthorized “superorgans,” a bioprinted organ black market, and to 
ensure a safe transplant process.  The FDA’s regulations regarding the con-
trol over the production of bioprinted organs is what allows them to enforce 
the other regulations discussed above. 
The FDA should suggest the establishment of an agency that will oversee 
bioprinting production.  This agency will be responsible for the enforce-
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ment of regulations regarding allocation of bioprinted organs, the order in 
which organs are distributed, consultation with insurance companies to es-
tablish a fair process for affording bioprinted organs, and ultimately have 
control over each functioning bioprinter. 
Bioprinters, like any printer, function through a software program.  In or-
der to be aware of what organs have been printed, the patients they have 
been printed for, and where they have been printed, the agency should cre-
ate a software used by every bioprinter.  This software will allow the agen-
cy access to regulate the use of the bioprinters without having physical con-
trol of the bioprinting process.  The agency would require that each 
bioprinter manufacturer install its software on each machine in order for the 
machine to be approved by the FDA.  The agency would then be able to 
review how each bioprinter is used and on which patients.  The software 
would require the input of each patient’s personal information and the rea-
son the organ is being created for the patient.   There would then be a fol-
low-up process to ensure that the patient actually was in medical need of 
the bioprinted organ and did in fact receive the organ.  This process would 
prevent facilities with access to bioprinters from abusing the technology.  
By having remote access to every function of the bioprinters, the govern-
ment will be able to effectively regulate the use of this new technology. 
CONCLUSION 
There is a need for immediate government regulation of bioprinting. The 
FDA has a habit of waiting for the technology to become mainstream prior 
to issuing regulation.  This method of regulation is insufficient with regards 
to new, advanced technologies, such as bioprinting.  It is important to re-
member that although bioprinting is the use of a printer to create a body 
part, the product is a living organ or tissue that will be implanted into the 
human body.  The FDA must adapt to changing technology and begin de-
veloping regulation now.  It is vital that the FDA considers how these 
bioprinted organs will be distributed, what conditions will make an individ-
ual eligible for bioprinting, and how to control the production and distribu-
tion of bioprinted organs.  Bioprinting has the potential to change how we 
look at organ transplants, but in order for it to be a successful method, the 
FDA must be proactive in regulating the technology. 
 
